RadNet Posts Record Q2 Revenue Up 8%

RadNet (RDNT) reported record Q2 2025 financial results, with revenue of $498.2 million and non-GAAP EPS of $0.31, both significantly surpassing analyst estimates. This outperformance was driven by robust advanced imaging volumes and strong growth in its digital health solutions. Consequently, management raised its full-year 2025 revenue and Adjusted EBITDA guidance, reflecting sustained operational momentum and strategic investments in AI and imaging technology.

Analysis

RadNet (NASDAQ:RDNT) reported a record-setting second quarter for 2025, significantly outperforming analyst expectations and demonstrating strong operational execution. The company posted revenue of $498.2 million, beating consensus by $9.2 million, and a non-GAAP EPS of $0.31, which was nearly double the $0.16 estimate. This performance was driven by an 8.4% year-over-year revenue increase, fueled primarily by a 9.0% rise in higher-margin advanced imaging volumes, which now comprise 27.5% of the procedural mix. Profitability also showed marked improvement, with the adjusted EBITDA margin expanding by 57 basis points to 16.3% due to the favorable service mix and operational leverage. The Digital Health segment continues to be a significant growth engine, with revenue surging 30.9% to $20.7 million; however, its profitability remains nascent as segment adjusted EBITDA grew only 4.1% due to a substantial increase in non-capitalized R&D spending. Strategically, the company is mitigating labor cost pressures through technology like its TechLive remote scanning system and is maintaining a robust balance sheet with a net debt to Adjusted EBITDA ratio of 0.96x. Based on this momentum, management confidently raised its full-year 2025 guidance for Imaging Center revenue and Adjusted EBITDA, signaling a positive outlook for its core business.

Key Decisions for Investors

• Given the significant Q2 earnings beat, raised full-year guidance for the core imaging business, and operational momentum in high-margin advanced imaging, investors could view the current trajectory as fundamentally positive.
• It is prudent to closely monitor the Digital Health segment's path to profitability, as the impressive 30.9% revenue growth is currently being reinvested into R&D, which limited its adjusted EBITDA growth to just 4.1%.
• The company's strong balance sheet, with a net debt to Adjusted EBITDA ratio of 0.96x, provides significant flexibility for continued strategic acquisitions and investments, but investors should track the impact of rising labor costs and the successful closure and integration of the pending iCAD deal.